Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Abstract

In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo. (Funded by Novo Nordisk and the National Institutes of Health; LEADER ClinicalTrials.gov number, NCT01179048.).

Keywords

Affiliated Institutions

• Sinai Hospital US
• Massachusetts General Hospital US
• George Washington University US
• Park Nicollet Clinic US
• London School of Hygiene & Tropical Medicine GB
• Ruhr University Bochum DE
• Lunenfeld-Tanenbaum Research Institute CA
• St. Josef-Hospital DE
• Friedrich-Alexander-Universität Erlangen-Nürnberg DE
• Cleveland Clinic London GB
• Washington University Medical Center US
• Imperial College London GB
• University of Toronto CA
• The University of Texas Southwestern Medical Center US
• Novo Nordisk (Denmark) DK
• University of North Carolina at Chapel Hill US

Related Publications